Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 166 of the 167 references it cites were found in a registry or an index; 118 of the 174 sources its claims cite were checked for support.

Advances on immunotherapy for osteosarcoma

Open access
Yu, Shengnan, Yao, Xudong · 2024 · Molecular Cancer

Abstract

Osteosarcoma is the most common primary bone cancer in children and young adults. Limited progress has been made in improving the survival outcomes in patients with osteosarcoma over the past four decades. Especially in metastatic or recurrent osteosarcoma, the survival rate is extremely unsatisfactory. The treatment of osteosarcoma urgently needs breakthroughs. In recent years, immunotherapy has achieved good therapeutic effects in various solid tumors. Due to the low immunogenicity and immunosuppressive microenvironment of osteosarcoma, immunotherapy has not yet been approved in osteosarcoma patients. However, immune-based therapies, including immune checkpoint inhibitors, chimeric antigen receptor T cells, and bispecfic antibodies are in active clinical development. In addition, other immunotherapy strategies including modified-NK cells/macrophages, DC vaccines, and cytokines are still in the early stages of research, but they will be hot topics for future study. In this review, we showed the functions of cell components including tumor-promoting and tumor-suppressing cells in the tumor microenvironment of osteosarcoma, and summarized the preclinical and clinical research results of various immunotherapy strategies in osteosarcoma, hoping to provide new ideas for future research in this field.

Overview

CoChat Summary

TL;DR

This review summarizes the immunosuppressive tumor microenvironment of osteosarcoma and the preclinical/clinical landscape of immunotherapies, including immune checkpoint inhibitors, CAR-modified cell therapies, vaccines, cytokines, and bispecific antibodies. It concludes that immunotherapy has not yet been approved for osteosarcoma and that single-agent approaches show limited efficacy, making biomarker-guided combination strategies the likely future direction.

Key findings

  • Osteosarcoma is the most common primary bone cancer in children and young adults, with an incidence of 3–5 per million per year; about 60% of patients are 10–20 years old. Localized disease has a 5-year survival of 60–70%, but metastatic or recurrent disease has only 20–30% 5-year survival.
  • The osteosarcoma TME is immunosuppressive: TAMs are the most abundant immune cells and account for approximately 50% of immune cells, with M2-type TAMs predominant. PD-L1 positivity was found in 13% of primary tumors, 25% of relapses, and 48% of metastases, and correlated with high T-cell infiltration.
  • Clinical ICI results are limited: in SARC028, 2 (5%) of 40 bone sarcoma patients had an objective response, including 1 (5%) of 22 osteosarcoma patients; a phase II pembrolizumab trial in 12 relapsed osteosarcoma patients showed no clinical benefit; and a pembrolizumab plus cyclophosphamide trial had only one partial response.
  • CAR-T and combination trials show some signals: in a HER2-CAR-T phase I/II trial of 19 patients (16 osteosarcoma), 4 of 17 evaluable patients had stable disease for 12 weeks to 14 months and median OS was 10.3 months; apatinib plus camrelizumab in 43 chemotherapy-refractory osteosarcoma patients had an ORR of 20.9% and 6-month PFS of 50.9%; MASCT-I plus camrelizumab and apatinib in 6 osteosarcoma patients had an ORR of 33.3%, DCR of 50.0%, and median PFS of 5.7 months.

Methods

  • Narrative review of the osteosarcoma immune microenvironment and immunotherapy strategies, including immune checkpoint inhibitors, CAR-T/CAR-M/CAR-NK cells, dendritic cell vaccines, cytokines, bispecific antibodies, and combination regimens.
  • Synthesizes preclinical studies and clinical trial results, with tables summarizing clinical trials of ICIs, adoptive cell therapies, and bispecific antibodies in osteosarcoma.
  • No primary patient cohort or new experimental data are reported; the analysis is a descriptive literature synthesis.

Limitations

  • The paper states that osteosarcoma has low immunogenicity and an immunosuppressive microenvironment, immunotherapy has not yet been approved for osteosarcoma, and many strategies remain in early or preclinical stages. It also notes that single immunotherapy has a low response rate and that CAR-NK/CAR-M therapies have not made promising progress in osteosarcoma.
  • Evident from the text: this is a narrative review without a systematic search strategy or quantitative meta-analysis, so selection and interpretation of cited studies may be subject to bias.
  • Evident from the text: many cited clinical trials are small, include mixed sarcoma populations with only subsets of osteosarcoma patients, or are terminated, withdrawn, suspended, or have unknown status, limiting the strength of conclusions about osteosarcoma-specific efficacy.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12943-024-02105-9

Cites

166 of 166 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Schematic illustration of the cellular components infiltrated in the osteosarcoma microenvironment. The TME of osteosarcoma contains tumor cells and a large number of non-tumor cells, embedded in altered extracellular matrix. The cells in the TME can be divided into tumor-promoting cells and tumor-suppressing cells.They exert their effects through different mechanisms in the microenvironment, but their functions are dynamically changing. Compared to the primary lesion, the expression of immune checkpoint molecules in the lung metastatic foci is increased, and there is an increase in immunosuppressive cells
Fig. 1 Schematic illustration of the cellular components infiltrated in the osteosarcoma microenvironment. The TME of osteosarcoma contains tumor cells and a large number of non-tumor cells, embedded in altered extracellular matrix. The cells in the TME can be divided into tumor-promoting cells and tumor-suppressing cells.They exert their effects through different mechanisms in the microenvironment, but their functions are dynamically changing. Compared to the primary lesion, the expression of immune checkpoint molecules in the lung metastatic foci is increased, and there is an increase in immunosuppressive cellsCC BY-NC-ND · PubMed Central
Fig. 2 The main immunotherapy strategies in osteosarcoma. In osteosarcoma, the relatively well-studied immunotherapies include: immune checkpoint inhibitors (with targets such as PD-1/PD-L1, CTLA-4, TIM-3, CD47 and TIGIT), adoptive cell therapies (such as CAR-T, CAR-M and CAR-NK), dendritic cell vaccines, and bispecific antibodies (targeting HER2 or GD2 and CD3). TAA: tumor-associated antigen
Fig. 2 The main immunotherapy strategies in osteosarcoma. In osteosarcoma, the relatively well-studied immunotherapies include: immune checkpoint inhibitors (with targets such as PD-1/PD-L1, CTLA-4, TIM-3, CD47 and TIGIT), adoptive cell therapies (such as CAR-T, CAR-M and CAR-NK), dendritic cell vaccines, and bispecific antibodies (targeting HER2 or GD2 and CD3). TAA: tumor-associated antigenCC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

107 Valid · 7 Not valid · 44 Not checked · 15 Own results and interpretations

97 more claims · 59 with their cited sources checked

Create a free account to see all 173 claims and to verify the 9 references still open.

See all claims — free account
  • It may state two separate claims as one. 66
  • Probably not a substantial claim. 8

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 167 references

Cited by

See all 270

Metadata

Authors
Yu, S., & Yao, X.
Affiliations
  • The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
  • Second Affiliated Hospital of Chongqing Medical University (CN)
Corresponding author
Yao, Xudong
Venue
Molecular Cancer
Published
2024-09-09
Volume
23
Issue
1
Pages
192-192
ISSN
1476-4598 (ISSN-L)
OpenAlex
W4402357381
Cited by
270
References
167
Citations by year
2026: 126 · 2025: 136 · 2024: 7
FWCI
44.96
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Cancer (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (82203007)
  • China Postdoctoral Science Foundation (2023MD744162)
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
Keywords
osteosarcoma, immunotherapy, tumor microenvironment, immune checkpoint inhibitors, chimeric antigen receptor T cells, bispecific antibodies, natural killer cells, macrophages
MeSH terms
Animals, Bone Neoplasms, Humans

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Advances on immunotherapy for osteosarcoma. https://app.cochat.ai/papers/10.1186/s12943-024-02105-9
The paper
Yu, S., & Yao, X. (2024). Advances on immunotherapy for osteosarcoma. Molecular Cancer. https://doi.org/10.1186/s12943-024-02105-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.